Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol Combined With Tislelizumab Plus GC as Neoadjuvant Therapy for Bladder Urothelial Carcinoma
NCT07353294Phase 1Enrolling by invitation
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in bladder urothelial carcinoma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jan 2026; status: enrolling by invitation.
02
Drugs
propranolol
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT07353294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353294.